Avextra Pharma

We are Avextra, a leading European vertically integrated medical cannabis operator dedicated to the development and production of regulator-approved medicines. Founded in 2019 and headquartered in Germany, we are driven by a mission to understand and harness the therapeutic potential of the cannabis plant to improve the quality of life for patients. We work in close collaboration with doctors, pharmacists, and researchers to develop and produce precisely formulated Cannabis-based Medicines that meet the highest pharmaceutical standards. Our commitment to scientific excellence is at the core of everything we do, as we strive to bridge the gap between traditional pharmaceutical practices and the evolving world of medical cannabis.

Our operations span the entire value chain, ensuring complete control and quality assurance from seed to patient. This includes cultivation in our purpose-built facility in Portugal, where we breed and grow selected cannabis genetics, to our EU-GMP certified extraction and manufacturing processes in Germany. We believe in the importance of evidence-based medicine and are actively involved in clinical trials and research initiatives to expand the evidence base for cannabis therapies. By combining our deep roots in the German phyto-pharmaceutical industry with modern medical research, we strive to provide patients with safe, effective, and consistent treatment options. We operate across continental Europe through an expansive distribution network, making our innovative products accessible to those who need them most. At Avextra, we are not just manufacturing medicines; we are shaping the future of patient care through dedication, innovation, and a relentless pursuit of quality.